Original Articles
Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities
Heli Halava, Maarit Jaana Korhonen, Risto Huupponen, Soko Setoguchi, Jaana Pentti, Mika Kivimäki and Jussi Vahtera
CMAJ June 23, 2014 cmaj.131807; DOI: https://doi.org/10.1503/cmaj.131807
Heli Halava
Departments of Public Health (Halava, Vahtera) and Pharmacology, Drug Development and Therapeutics (Korhonen, Huupponen), University of Turku, and Turku University Hospital (Huupponen Vahtera), Turku, Finland; Duke Clinical Research Institute (Setoguchi), Duke University School of Medicine, Durham, NC; the Finnish Institute of Occupational Health (Pentti, Vahtera), Turku, Finland; the Department of Epidemiology and Public Health (Kivimäki), University College London, London, UK
Maarit Jaana Korhonen
Departments of Public Health (Halava, Vahtera) and Pharmacology, Drug Development and Therapeutics (Korhonen, Huupponen), University of Turku, and Turku University Hospital (Huupponen Vahtera), Turku, Finland; Duke Clinical Research Institute (Setoguchi), Duke University School of Medicine, Durham, NC; the Finnish Institute of Occupational Health (Pentti, Vahtera), Turku, Finland; the Department of Epidemiology and Public Health (Kivimäki), University College London, London, UK
Risto Huupponen
Departments of Public Health (Halava, Vahtera) and Pharmacology, Drug Development and Therapeutics (Korhonen, Huupponen), University of Turku, and Turku University Hospital (Huupponen Vahtera), Turku, Finland; Duke Clinical Research Institute (Setoguchi), Duke University School of Medicine, Durham, NC; the Finnish Institute of Occupational Health (Pentti, Vahtera), Turku, Finland; the Department of Epidemiology and Public Health (Kivimäki), University College London, London, UK
Soko Setoguchi
Departments of Public Health (Halava, Vahtera) and Pharmacology, Drug Development and Therapeutics (Korhonen, Huupponen), University of Turku, and Turku University Hospital (Huupponen Vahtera), Turku, Finland; Duke Clinical Research Institute (Setoguchi), Duke University School of Medicine, Durham, NC; the Finnish Institute of Occupational Health (Pentti, Vahtera), Turku, Finland; the Department of Epidemiology and Public Health (Kivimäki), University College London, London, UK
Jaana Pentti
Departments of Public Health (Halava, Vahtera) and Pharmacology, Drug Development and Therapeutics (Korhonen, Huupponen), University of Turku, and Turku University Hospital (Huupponen Vahtera), Turku, Finland; Duke Clinical Research Institute (Setoguchi), Duke University School of Medicine, Durham, NC; the Finnish Institute of Occupational Health (Pentti, Vahtera), Turku, Finland; the Department of Epidemiology and Public Health (Kivimäki), University College London, London, UK
Mika Kivimäki
Departments of Public Health (Halava, Vahtera) and Pharmacology, Drug Development and Therapeutics (Korhonen, Huupponen), University of Turku, and Turku University Hospital (Huupponen Vahtera), Turku, Finland; Duke Clinical Research Institute (Setoguchi), Duke University School of Medicine, Durham, NC; the Finnish Institute of Occupational Health (Pentti, Vahtera), Turku, Finland; the Department of Epidemiology and Public Health (Kivimäki), University College London, London, UK
Jussi Vahtera
Departments of Public Health (Halava, Vahtera) and Pharmacology, Drug Development and Therapeutics (Korhonen, Huupponen), University of Turku, and Turku University Hospital (Huupponen Vahtera), Turku, Finland; Duke Clinical Research Institute (Setoguchi), Duke University School of Medicine, Durham, NC; the Finnish Institute of Occupational Health (Pentti, Vahtera), Turku, Finland; the Department of Epidemiology and Public Health (Kivimäki), University College London, London, UK